KPIs & Operating Metrics(New)
Alliance Revenue Breakdown AnnualAlliance Revenue By CategoryAndexxa Revenue By RegionAndexxa Revenue By Region AnnualArimidex Revenue By Region AnnualAssets By RegionAtacand Revenue By Region AnnualBevespi Revenue By RegionBevespi Revenue By Region AnnualBeyfortus Revenue By RegionBeyfortus Revenue By Region AnnualBreakdown Of AssetsBreztri Revenue By RegionBreztri Revenue By Region AnnualBrilinta Revenue By RegionBrilinta Revenue By Region AnnualBydureon Revenue By RegionBydureon Revenue By Region AnnualByetta Revenue By Region AnnualCalquence Revenue By RegionCalquence Revenue By Region AnnualCardiovascular And Metabolic DiseasesCardiovascular And Metabolic Diseases AnnualCardiovascular And Metabolic Diseases+B2Casodex Revenue By Region AnnualCollaboration Revenue By CategoryCollaboration Revenue By Category AnnualCrestor Revenue By RegionCrestor Revenue By Region AnnualDaliresp Revenue By RegionDaliresp Revenue By Region AnnualEmployee StatisticsEnhertu Revenue By RegionEnhertu Revenue By Region AnnualFarxiga Revenue By RegionFarxiga Revenue By Region AnnualFasenra Revenue By RegionFasenra Revenue By Region AnnualFaslodex Revenue By RegionFaslodex Revenue By Region AnnualFlumist Revenue By RegionFlumist Revenue By Region AnnualGlobal Pharmaceutical Sales By Region AnnualImfinzi Revenue By RegionImfinzi Revenue By Region AnnualIressa Revenue By Region AnnualKanuma Revenue By RegionKanuma Revenue By Region AnnualKoselugo Revenue By RegionKoselugo Revenue By Region AnnualLokelma Revenue By RegionLokelma Revenue By Region AnnualLynparza Revenue By RegionLynparza Revenue By Region AnnualNew Crvm Revenue By RegionNew Crvm Revenue By Region AnnualNexium Revenue By RegionNexium Revenue By Region AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Oncology Revenue By RegionOncology Revenue By Region AnnualOncology SalesOncology Sales AnnualOnglyza Revenue By RegionOnglyza Revenue By Region AnnualOperating Profit/ (Loss) By Geographic AreasOperating Profit/ (Loss) Margin By Geographic AreasOpex As A % Of RevenueOPEX SegregationOrpathys Revenue By RegionOrpathys Revenue By Region AnnualOther Medicines SalesOther Product Sales AnnualOther Revenue By RegionOther Revenue By Region AnnualOthers Crvm Revenue By RegionOthers Crvm Revenue By Region AnnualOthers Medicines Revenue By RegionOthers Medicines Revenue By Region AnnualOthers Oncology Revenue By RegionOthers Oncology Revenue By Region AnnualOthers Respiratory Revenue By RegionOthers Respiratory Revenue By Region AnnualProduct Revenue Breakdown AnnualProduct Revenue By Region AnnualProduct Revenue By Region Annual %Product Revenue By SegmentProduct Revenue By Segment %Property, Plant And Equipment BreakdownProperty, Plant And Equipment By RegionPulmicort Revenue By RegionPulmicort Revenue By Region AnnualRare Disease Product SalesRare Disease Revenue By RegionRare Disease Revenue By Region AnnualRespiratory Revenue By RegionRespiratory Revenue By Region AnnualRespiratory SalesRespiratory Sales AnnualRevenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By Geogrtaphic AreasRevenue By RegionRevenue By Region %Roxadustat Revenue By RegionSaphnelo Revenue By RegionSaphnelo Revenue By Region AnnualSeloken/Toprol Xl Revenue By RegionSeloken/Toprol Xl Revenue By Region AnnualSoliris Revenue By RegionSoliris Revenue By Region AnnualStrensiq Revenue By RegionStrensiq Revenue By Region AnnualSymbicort Revenue By RegionSymbicort Revenue By Region AnnualSynagis Revenue By RegionSynagis Revenue By Region AnnualTagrisso Revenue By RegionTagrisso Revenue By Region AnnualTezspire Revenue By RegionTezspire Revenue By Region AnnualTotal Assets By Geographic AreaUltomiris Revenue By RegionUltomiris Revenue By Region AnnualVaccines & Immune Revenue By RegionVaccines & Immune Revenue By Region AnnualVaccines & Immune SalesVaxzevria Revenue By RegionVaxzevria Revenue By Region AnnualZoladex Revenue By RegionZoladex Revenue By Region Annual
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Total Debt Growth (1y)Total Debt Growth (3y)Total Debt Growth (5y)
Income Statement
Astrazeneca (AZN) Property, Plant & Equipment (Net) Growth (3y) (2018 - 2025)
Generated on {Timestamp}
© BusinessQuant.com
Generated on {Timestamp}
Powered by 
Peer Comparison
Historic Data
Download Data 🔒| Date | Value |
|---|---|